Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib

Khalid Shoumariyeh
Nikolas von Bubnoff
Department of Hematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany

Abstract: Treatment of chronic myeloid leukemia (CML) has undergone dramatic changes in the last decade. Dissecting the molecular pathways that lead to the development of this disease resulted in the development of targeted therapy against the molecular driver of CML, namely the aberrantly activated tyrosine kinase BCR-ABL1. By introducing the tyrosine kinase inhibitor imatinib to the treatment repertoire, the natural course of the disease has been dramatically altered and overall survival of patients with CML prolonged substantially. Nevertheless, a significant number of patients are primarily resistant, acquire resistance during the course of their disease, or do not tolerate the intake of imatinib due to adverse effects. Second-generation tyrosine kinase inhibitors were developed in an attempt to overcome these problems. Dasatinib is a potent oral kinase inhibitor that was originally developed as an Src-kinase inhibitor but exhibited promising potency against BCR-ABL1 as well. Phase I and II trials demonstrated efficacy in patients failing imatinib, and thus dasatinib was approved in 2006 for the treatment of imatinib-resistant or -intolerant patients with chronic-phase CML harboring the BCR-ABL1 fusion protein. It has since shown promising efficacy and good overall tolerability in subsequent clinical trials, including the Phase III first-line DASISION trial that led to the extension of its approval for first-line treatment of chronic-phase CML. The following review summarizes the available data on the long-term efficacy and safety of dasatinib as a second-line therapy in chronic-phase CML.

Keywords: BCR-ABL1, TKI, CML-CP, second-line treatment

Introduction to the management of chronic-phase chronic myeloid leukemia

Chronic myeloid leukemia (CML) arises by clonal expansion of an aberrant myeloid precursor cell in the bone marrow. It is usually classified into three distinct clinical stages, namely the chronic phase (CP), acceleration phase, and blast crisis, the latter of which resembles acute leukemia and displays a very poor prognosis. The pathogenetic culprit in CML is the balanced reciprocal translocation between chromosomes 9 and 22 (t[9;22][q34;11]) generating the so-called Philadelphia chromosome, detectable in approximately 95% of all CML patients. On a molecular level, the translocation results in the fusion of the c-abl proto-oncoprotein from chromosome 9 with the breakpoint cluster (BCR)-gene from chromosome 22, yielding an aberrantly activated tyrosine-kinase termed BCR-ABL1. This de novo oncoprotein drives the malignant transformation of the myeloid precursor cell by phosphorylation of downstream effector proteins.
pathways responsible for growth and increased survival of the precursor cells.6

Imatinib in the clinic
In 2002 treatment of CML-CP underwent a paradigm shift by the introduction and approval of imatinib mesylate (STI571, Gleevec©; Novartis Pharmaceuticals, Basel, Switzerland), a selective small molecule inhibitor of BCR-ABL1. Additionally, STI571 showed in vitro inhibitory activity against the α- and β-platelet derived growth factor receptors and c-Kit.7 Imatinib specifically binds to the adenosine triphosphate (ATP)-pocket of BCR-ABL1 in its closed conformation, thereby blocking its kinase function.8 Several clinical studies demonstrated a durable hematologic and cytogenetic response with a low toxicity profile for imatinib.9,10 Follow-up data from the Phase III International Randomized Study of Interferon versus STI571 after 5 and 8 years have confirmed the persistent efficacy of imatinib treatment, with an estimated overall survival (OS) of 85%, while experienced side effects were mostly mild to moderate.11,12 However, 15%–20% of Philadelphia chromosome-positive (Ph+) CML-CP patients are resistant to imatinib or develop a resistance in the course of their disease.12 Rates of imatinib-resistance rise substantially upon disease progression to about 80% in patients with blast crisis.13 The most common molecular cause of resistance to imatinib is the occurrence of point mutations that yield an open conformation of the tyrosine kinase and thus alter the binding of imatinib to the BCR-ABL1 oncoprotein. The majority of imatinib-resistance mutations yield amino acid substitutions at one of the following seven residues: M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V, which are located in the ABL tyrosine kinase domain.13 Amino acids 248–256 comprise the so-called P-loop, the highly conserved region in the kinase domain that is responsible for binding of ATP. Mutations in one of these residues are found in almost half of the resistant patients harboring a mutation.13 In about 10% of cases, resistance to imatinib occurs due to amplification of the BCR-ABL1 oncogene.14,15 BCR-ABL-independent pathways and lack of adherence to the treatment regimens have also been implicated in some cases of resistance.16,17 Imatinib resistance is associated with a negative prognostic impact and reduces progression-free survival (PFS) as well as OS of patients with CML.18 On the basis of these observations, a search for more potent substances to counteract the permanently activated kinase in CML led to the discovery of new second-generation tyrosine kinase inhibitors (TKI).

Dasatinib in the clinic
Dasatinib (BMS-354825, Sprycel©; Bristol-Myers Squibb, NY, USA) and nilotinib (Tasigna©; Novartis Pharmaceuticals, NJ, USA) are two orally available TKI that showed efficacy and were approved for the second-line treatment of CML-CP after imatinib failure due to resistance or intolerance. Dasatinib was originally developed as an Src-kinase inhibitor, but displayed potent activity as an ABL-inhibitor as well. Moreover, it also binds and suppresses other kinases such as c-Kit or platelet derived growth factor β-receptor.19 As stated above, to exert its inhibitory function, imatinib requires the ABL tyrosine kinase to be in its closed and thus inactive conformation, whereas dasatinib inhibits the kinase in its active conformation.20 In vitro data revealed superior efficacy on wild-type BCR-ABL1 by BMS-354825 compared to imatinib and, intriguingly, also exhibited activity against most of the mutations conferring imatinib-resistance observed in CML patients. The only entirely insensitive BCR-ABL1 mutant found was T315I.21,22 Mutants that conferred reduced sensitivity to dasatinib included F317L, V299L, and T315A.23,24 Ensuing preclinical and clinical studies demonstrated great potency as dasatinib treatment led to complete hematologic response (CHR) as well as major cytogenetic response (MCyR) in patients with CML-CP resistant or intolerant to imatinib.25 Dasatinib showed efficacy in all stages of imatinib-resistant and -intolerant CML.26 In 2006 the US Food and Drug Administration approved dasatinib for second-line treatment of patients with CML-CP. Approval of dasatinib was subsequently extended to all phases of CML as well as Ph+ acute lymphoblastic leukemia (ALL) and resistance or intolerance to previous treatment including imatinib, and recently, to newly diagnosed CML-CP.27 In this review, we summarize the data on the efficacy and safety of dasatinib as a second-line treatment in CML-CP patients resistant or intolerant to treatment with imatinib.

Efficacy of dasatinib in CML-CP resistant or intolerant to imatinib
The clinical studies evaluating dasatinib as a second-line treatment in CML-CP after imatinib failure used for this review are summarized in Table 1.

Phase I trial
The first clinical study to report on dasatinib in a second-line setting in CML-CP was conducted by Talpaz et al.26 A total of 84 patients with all phases of CML and Ph+ ALL and a history of imatinib intake were selected to receive dasatinib
in this Phase I dose-escalating study, which focused on the safety and tolerability of dasatinib and gathered evidence for the clinical activity of this second-generation TKI in CML patients after imatinib failure. Of the 84 patients enrolled between November 2003 and April 2005, 40 had CML-CP. An update after a follow-up of at least 27 months was presented as an abstract at the annual meeting of the American Society of Hematology in 2007.\textsuperscript{28} Administered dose of dasatinib ranged between 15 and 180 mg taken daily either as once-daily or twice-daily.

After 27 months of follow-up, 91\% of CML-CP patients achieved a CHR and 51\% a MCyR, with a complete cytogenetic response (CCyR) measured in 44\% (Table 2). There was no statistically significant difference between rates of CCyR for the once-daily and twice-daily schedule arms. In patients who achieved a MCyR during the first year of treatment with dasatinib PFS and OS after 36 months were 87\% and 94\%, respectively. PFS and OS declined to 28\% and 68\%, respectively, in those patients who achieved no MCyR after 1 year of study treatment (Table 2).\textsuperscript{28} As expected by results from preclinical studies, dasatinib treatment achieved hematologic and cytogenetic responses across all BCR-ABL1 mutations found except for T315I.\textsuperscript{28}

### Phase II trials

The long-term safety profile and efficacy of dasatinib in patients with Ph+ CML-CP were investigated on a larger scale by the START (SRC/ABL Tyrosine Kinase Inhibition Activity: Research Trials of Dasatinib) program, which consisted of four single arm international, multicenter, open-label Phase II clinical studies of dasatinib in all phases of imatinib-resistant or -intolerant CML and Ph+ ALL as well as one randomized trial comparing dasatinib with high-dose imatinib in patients with all phases of CML after failure of first-line treatment with imatinib.\textsuperscript{29–36} Initial results from these clinical studies led to dasatinib’s approval as a second-line treatment in these entities.

The START in Chronic Phase Patients (START-C) trial assessed efficacy and tolerability of dasatinib in patients with CML-CP with resistance or intolerance to imatinib. In total, 387 patients with CML-CP previously treated with imatinib but intolerant (n=99) or who developed resistance (n=288) were enrolled in this study. Dasatinib was administered at a dose of 140 mg/day (70 mg twice-daily). Efficacy was measured by the primary endpoint, the MCyR rate.\textsuperscript{31} The follow-up data after 2 years reported a CHR in 91\% and a MCyR in 62\% of patients, with a CCyR rate of 53\%.

### Table 1

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment schedule</th>
<th>Number of patients (CML-CP)</th>
<th>Follow-up</th>
<th>Treatment schedule</th>
<th>Number of patients (CML-CP)</th>
<th>Follow-up</th>
<th>Treatment schedule</th>
<th>Number of patients (CML-CP)</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>START-C</td>
<td>15–180 mg (QD or BID)</td>
<td>n=40</td>
<td>27 months</td>
<td>70 mg (BID)</td>
<td>n=387</td>
<td>24 months</td>
<td>70 mg (BID)</td>
<td>n=101</td>
<td>24 months</td>
</tr>
<tr>
<td>START-R</td>
<td>27/36 months</td>
<td></td>
<td></td>
<td>100 mg QD or 50 mg BID or 140 mg QD or 70 mg BID</td>
<td>n=662</td>
<td>72 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>START-C</td>
<td>27/36 months</td>
<td></td>
<td></td>
<td>100 mg QD or 50 mg BID or 140 mg QD or 70 mg BID</td>
<td>n=662</td>
<td>72 months</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BID, twice daily; CML-CP, chronic phase-chronic myeloid leukemia; QD, once daily; START-C, SRC/ABL Tyrosine Kinase Inhibition Activity: Research Trials of Dasatinib; START-R, START randomized trial.

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>CA180-002\textsuperscript{26,28}</th>
<th>START-C \textsuperscript{29–31}</th>
<th>START-R \textsuperscript{35,36}</th>
<th>CA180-034\textsuperscript{37–40}</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHR</td>
<td>91%</td>
<td>91%</td>
<td>93%</td>
<td>NA</td>
</tr>
<tr>
<td>MCyR</td>
<td>51%</td>
<td>62%</td>
<td>53%</td>
<td>59%</td>
</tr>
<tr>
<td>CCyR</td>
<td>44%</td>
<td>53%</td>
<td>44%</td>
<td>41%</td>
</tr>
<tr>
<td>MMR</td>
<td>NA</td>
<td>47%</td>
<td>29%</td>
<td>43%</td>
</tr>
<tr>
<td>PFS</td>
<td>87%/28%</td>
<td>80%</td>
<td>86%</td>
<td>49%</td>
</tr>
<tr>
<td>OS</td>
<td>94%/68%</td>
<td>94%</td>
<td>NA</td>
<td>71%</td>
</tr>
<tr>
<td>Time point of analysis</td>
<td>27/36 months</td>
<td>24 months</td>
<td>72 months</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** \textsuperscript{a}Data shown for patients treated in the 100 mg QD cohort (n=167); \textsuperscript{b}analysis after 36 months, PFS and OS for patients that achieved a MCyR during the first year of treatment; \textsuperscript{c}analysis after 36 months, PFS and OS for patients that did not achieve a MCyR during the first year of treatment.

**Abbreviations:** CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; MCyR, major cytogenetic response; MHR, major hematological response; MMR, major molecular response; NA, not available; OS, overall survival; PFS, progression-free survival; QD, once daily; START-C, SRC/ABL Tyrosine Kinase Inhibition Activity: Research Trials of Dasatinib in Chronic Phase Patients; START-R, START randomized trial.
Major molecular response (MMR), defined by transcript levels of BCR-ABL \(^{35}\) \(\leq 0.10\), was achieved by 47% of patients (Table 2). In imatinib-resistant patients, MCyR rates were 55%. MCyR was maintained by 88% of patients at 24 months. Rates of CCyR and MMR in patients intolerant to imatinib were both 78%. Dasatinib-induced responses were durable. At 24 months, PFS in imatinib-resistant and -intolerant patients was 75% and 94%, respectively. \(^{31}\) OS after 24 months was 94%, with 92% survivors in the imatinib-resistant group and 100% in the imatinib-intolerant cohort. Hematological and cytogenetic response was observed across all BCR-ABL genotypes, with the exception of the T315I mutation. \(^{31}\)

In another international, multicenter, randomized, open-label, Phase II trial conducted by the START consortium, treatment responses to dasatinib 70 mg twice-daily (n=101) versus high-dose imatinib (800 mg, n=49) were investigated in a comparative study in imatinib-resistant CML-CP. \(^{35,36}\) The 150 patients randomized (2:1) in the START (START-R) trial had previously been treated with doses of imatinib of 400 to 600 mg daily. Crossover was possible upon progression, lack of MCyR, or intolerance to the treatment to which the patients had been allocated. Randomized patients had been substantially pretreated, having undergone prior therapy with hydroxyurea/anagrelide and/or interferon as well as chemotherapy and even bone marrow transplantation. \(^{36}\) Prior to study entry, the majority of patients had been on imatinib for at least 1–3 years or longer (90% in both arms). In the dasatinib arm, 51 and 6 patients had a CHR and a MCyR, respectively. In the imatinib arm, 27 patients had a CHR at baseline. After a 2 year follow-up, results clearly favored dasatinib over high-dose imatinib in imatinib-resistant CML-CP. Dasatinib led to higher rates of CHR (93% versus 82%), MCyR (53% versus 33%) as well as CCyR (44% versus 18%). MCyR was maintained in 90% of the dasatinib-treated and in 74% of those in the high-dose imatinib cohort after 18 months. \(^{36}\) For patients that entered the study without a CHR, the CHR rate after 24 months was 86% in the dasatinib arm compared to 72% in patients treated with 800 mg of imatinib. In those without a MCyR at baseline, MCyR rates were 52% with dasatinib and 33% with high-dose imatinib. Of those who achieved a MCyR, 45% and 18% of the dasatinib- and imatinib-treated patients, respectively, retained the MCyR after 24 months. \(^{36}\) CCyR rates were 42% and 18% with dasatinib and imatinib, respectively, in patients not showing a CCyR at baseline. Additionally, those treated with dasatinib achieved a higher MMR than the cohort treated with high-dose imatinib (29% versus 12%). Furthermore, in patients presenting a CCyR, the rate of MMR in those treated with dasatinib was 64% compared to 56% in the high-dose imatinib group. Crossover from the high-dose imatinib to the dasatinib arm occurred in 39 patients (80%), whereas only 20% of the patients in the dasatinib cohort crossed over to the high-dose imatinib arm. The MCyR rate after crossover was 49% with dasatinib and 15% with 800 mg of imatinib. Reasons for discontinuing dasatinib or high-dose imatinib treatment after achieving a MCyR were loss of MCyR in 5% and 6%, respectively, or treatment intolerance in 3% of patients receiving dasatinib and 4% of those receiving imatinib. \(^{36}\)

**Phase III trial**

In the Phase III dose-optimization study, CA180-034, 670 patients with imatinib-resistant (74%) or -intolerant (26%) CML-CP were randomized to either receive dasatinib 100 mg once-daily, 50 mg twice-daily, 140-mg once-daily, or 70 mg twice-daily. Of the 670 randomly assigned patients, 662 underwent actual treatment in one of the four dosing arms. Follow-up data from the CA180-034 trial have been published regularly. \(^{37–40}\) The most recent analysis was conducted after 72 months, yielding the longest follow-up data on CML-CP patients on dasatinib after imatinib failure. \(^{40}\) After 72 months, 28% (n=188) were still on study treatment and eligible for analysis. Of the 188 patients, 144 (77%) received a once-daily dose. Analysis after 72 months showed that the rates of MCyR (59% versus 55%, respectively) and CCyR (41% versus 45%, respectively) were similar in the 100 mg once-daily and 70 mg twice-daily regimens. \(^{40}\) MMR was achieved by 43% of patients receiving dasatinib at a dose of 100 mg daily compared to 40% in all other arms. The estimated PFS and OS rates at the 6 year follow-up were 49%/71%, 51%/74%, 40%/77%, and 47%/70% for the 100 mg once-daily, 50 mg twice-daily, 140 mg once-daily, and 70 mg twice-daily treatment schedule, respectively. In patients with BCR-ABL \(^{38}\) \(\leq 10\%\) versus >10% at 3 months, rates of PFS and OS were higher after 6 years. The estimated OS rate without transformation to accelerated or blast phase on study treatment was 78% (76% with 100 mg once-daily, 80% with 50 mg twice-daily, 83% with 140 mg once-daily, and 74% with 70 mg twice-daily). \(^{40}\) During the 6 year follow-up period, ten patients eligible for analysis treated in the 100 mg once-daily study arm demonstrated transformation to accelerated phase or blast phase (nine imatinib-resistant and one imatinib-intolerant). At baseline, 22 patients with more than one dasatinib-resistant mutation were revealed by mutational assessment.
All of those patients were off study treatment at the follow-up after 6 years.40

Safety of dasatinib in CML-CP resistant or intolerant to imatinib
Phase I trial
In the Phase I study conducted by Talpaz et al, treatment-related hematological toxicity was common in CML-CP patients treated with dasatinib.26 After a median follow-up of 12 months, grade 3 or 4 neutropenia and thrombocytopenia were registered in 45% and 35%, respectively (Table 3). This myelosuppression necessitated treatment interruption in 60% and dose reduction in 25% of patients.28 The most common grade 3 or 4 nonhematological adverse event during study treatment was pleural effusion, which occurred in 15 patients and required supportive measures including diuretics, thoracocentesis, and pleurodesis.28 Remaining adverse events were mostly grade 1 or 2 and were diarrhea, peripheral edema, dyspnea, and headache (Table 4). Grade 3 or 4 liver function abnormalities developed in seven patients but did not require any dose adjustments and resolved by themselves. About 60% of patients had grade 1 or 2 asymptomatic hypocalcemia. There were no study withdrawals due to adverse events.28

Phase II trials
In line with results from the Phase I study in the START-C trial, grade 3–4 hematologic toxicities were usually observed during the first phases of therapy and included thrombocytopenia (49%) and neutropenia (50%). Nonhematological adverse events were generally mild to moderate in severity. Grade 3–4 nonhematological treatment-related side effects primarily consisted of pleural effusion (9%), dyspnea (6%), bleeding (4%), diarrhea (3%), and fatigue (3%).31

In the START-R trial, grade 3 or 4 adverse events related to the treatment occurred more often in conjunction with dasatinib treatment (61%) than high-dose imatinib treatment (39%). The most frequently observed hematological grade 3 or 4 adverse events were neutropenia, thrombocytopenia, and leucopenia and were more frequent with dasatinib than with high-dose imatinib (Table 3). Nonhematological toxicities were mostly grade 1 or 2. Grade 3 or 4 nonhematological events consisted of fluid retention, especially pleural effusion, diarrhea, headache, musculoskeletal pain, infection, and fatigue (Table 4).36

Phase III trial
Of all the dosing schedules, 100 mg of dasatinib taken once-daily displayed the best safety profile in the CA180-034 trial, and thus led to lower rates of treatment discontinuation due to drug toxicity compared to the then standard dose of 70 mg twice-daily (11% versus 21%).40 The most common hematologic adverse events of any grade reported with dasatinib 100 mg once-daily were anemia (89%), neutropenia (63%), and thrombocytopenia (60%). Grade 3–4 hematologic side effects tended to occur early during treatment (in the first year).40 Nonhematological adverse events were generally of grade 1 or 2 and usually appeared within the first 2 years of treatment. In line with the Phase I and II studies, the most frequent nonhematological toxicities associated with intake of dasatinib 100 mg once-daily were musculoskeletal pain (49%), headache (47%), infections (47%), diarrhea (41%), fatigue (37%), pleural effusions (25.3%), hemorrhage (24.9%), and nausea (22.4%) (Table 4).40 Grade 3 or 4 pleural effusions occurred in 5.3% of patients treated with 100 mg daily, which was less frequent than in all other schedule arms (6.6%). After 72 months, 7% of patients withdrew from study treatment due to pleural effusions in the 100 mg once-daily arm compared to 9% in all other arms.40 Two patients suffered from pulmonary arterial hypertension, although no diagnostic right-heart catheterization was performed. The results of this trial established 100 mg once-daily as the standard starting dose of dasatinib in CML-CP showing resistance or intolerance to imatinib.

Table 3 Dasatinib-related hematological adverse events in CML-CP after imatinib failure

<table>
<thead>
<tr>
<th>Dosing schedule</th>
<th>CA180-002</th>
<th>START-C</th>
<th>START-R</th>
<th>CA180-034</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1–180 mg (QD or BID)</td>
<td>Grade 3/4</td>
<td>70 mg (BID)</td>
<td>Grade 3/4</td>
<td>100 mg (QD)</td>
</tr>
<tr>
<td>Anemia</td>
<td>NA</td>
<td>22%</td>
<td>20%</td>
<td>13%</td>
</tr>
<tr>
<td>Leukocytopenia</td>
<td>NA</td>
<td>27%</td>
<td>24%</td>
<td>18%</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>45%</td>
<td>50%</td>
<td>63%</td>
<td>36%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>35%</td>
<td>49%</td>
<td>57%</td>
<td>24%</td>
</tr>
</tbody>
</table>

Notes: *Data after a median follow-up of 12 months; †data after a median follow-up of 15.2 months; ‡data after a 24-month follow-up.

Abbreviations: BID, twice daily; CML-CP, chronic-phase chronic myeloid leukemia; NA, not available; QD, once daily; START-C, SRC/ABL Tyrosine Kinase Inhibition Activity: Research Trials of Dasatinib in Chronic Phase Patients; START-R, START randomized trial.
since that dose was associated with fewer treatment-related toxicities, while showcasing efficacy comparable to that of 70 mg twice-daily.

### Conclusion

CML constitutes the first disease in which better knowledge of the underlying molecular pathogenesis led to the development of a specific targeted therapy in the form of imatinib. Long-term follow-up data from clinical studies testing imatinib in CML-CP identified a group of patients with CML that does not profit sufficiently from this tailored inhibitor due to primary or secondary resistance to imatinib or intolerance because of adverse effects. Different strategies have been deployed to overcome these obstacles in TKI-based CML treatment. The available therapeutic options in the resistant setting were limited until new and more potent TKI were developed, such as dasatinib, nilotinib, and recently bosutinib and ponatinib, as dasatinib, nilotinib, and recently bosutinib and ponatinib, with ponatinib currently the only TKI with T315I activity.

Dasatinib displays more potent suppressive activity against wild-type BCR-ABL than imatinib and was approved for the second-line treatment of CML-CP in patients intolerant or resistant to imatinib. The long-term data presented in this review confirm the notion that dasatinib exhibits durable efficacy in CML-CP after imatinib failure, while maintaining a relatively safe toxicity profile, with adverse events being mostly of grade 1 or 2. Consistent with preclinical data from in vitro investigations, dasatinib demonstrated efficacy in most genetic mutations conferring imatinib-resistance, with the exception of T315I.

Noteworthy, sequential treatment with dasatinib in a second-line setting after resistance-induced failure of imatinib is associated with the emergence of drug-specific BCR-ABL kinase domain mutations not detectable prior to the initiation of dasatinib such as V299L, T315A, F317L/V/I/C, and compound mutations. These mutations are associated with a poor outcome of dasatinib treatment while acquired mutations in Y253H, E255K/V, F359V/C/I, or T315I are frequently detected in patients with failure during nilotinib treatment. Intriguingly, the presence of certain mutations is not always a good predictor of treatment outcome, as shown by a case report by Oyekunle et al. In their presented case, a F317L mutation was first detected while a CML-CP patient was undergoing treatment with dasatinib. Treatment with dasatinib was continued, and a sustained MMR was achieved while the F317L mutation was not detectable in subsequent kinase domain mutation analyses, suggesting other factors involved in determining treatment outcome. Nonetheless, recent European Leukemia Network guidelines recommend a mutational analysis for possible BCR-ABL1 kinase domain point mutations if hematologic or cytogenetic failure occurs during TKI treatment to identify the most suitable TKI based on the identified mutations.

### Table 4 Dasatinib-related nonhematological adverse events in CML-CP after imatinib failure

<table>
<thead>
<tr>
<th>Dosing schedule</th>
<th>CA180-00228,38</th>
<th>START-C29-32</th>
<th>START-R33,34</th>
<th>CA180-03437-40</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up</td>
<td>15–180 mg daily (QD or BID)</td>
<td>70 mg daily (BID)</td>
<td>70 mg daily (BID)</td>
<td>100 mg daily (QD)</td>
</tr>
<tr>
<td>Grade</td>
<td>All grades</td>
<td>Grade 3/4</td>
<td>All grades</td>
<td>Grade 3/4</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>13%</td>
<td>0</td>
<td>27%</td>
<td>9%</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>18%</td>
<td>0</td>
<td>18%</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>10%</td>
<td>0</td>
<td>30%</td>
<td>6%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Fever</td>
<td>NA</td>
<td>NA</td>
<td>16%</td>
<td>1%</td>
</tr>
<tr>
<td>Infection</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>18%</td>
<td>0</td>
<td>37%</td>
<td>3%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>NA</td>
<td>NA</td>
<td>14%</td>
<td>1%</td>
</tr>
<tr>
<td>Nausea</td>
<td>5%</td>
<td>0</td>
<td>25%</td>
<td>1%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>0</td>
<td>11%</td>
<td>0.5%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>8%</td>
<td>2%</td>
<td>31%</td>
<td>3%</td>
</tr>
<tr>
<td>Headache</td>
<td>10%</td>
<td>0</td>
<td>32%</td>
<td>1%</td>
</tr>
<tr>
<td>Skin rash</td>
<td>2%</td>
<td>0</td>
<td>26%</td>
<td>0.5%</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Notes:** Data for “all grades” after a median follow-up of 15.2 months; data from a 24-month follow-up presented as an abstract at the 2008 American Society of Clinical Oncology Annual Meeting. 

**Abbreviations:** BID, twice daily; CML-CP, chronic-phase chronic myeloid leukemia; NA, not available; QD, once daily; START-C, SRC/ABL Tyrosine Kinase Inhibition Activity: Research Trials of Dasatinib in Chronic Phase Patients; START-R, START randomized trial.
Dasatinib led to a rapid and deep hematological, cytological, and molecular response in both first- and second-line treatment of CML-CP. Response rates at 3 and 6 months after treatment initiation are being increasingly recognized as predictive markers for low transformation rates into accelerated or blast phases, translating into better long-term outcome and survival. Moreover, an early switch to dasatinib after imatinib failure seems advisable to yield an optimal response and facilitate best long-term outcome, as shown by Quintás-Cardama et al in their retrospective pooled analysis of the START-C, START-R, and CA180-034 trials. Their analysis revealed that the best outcome after progression on imatinib treatment was achieved if dasatinib was administered early after MCyR loss instead of switching to dasatinib after the loss of both MCyR and CHR.

In the Phase III dose-optimizing study by Shah et al, 100 mg of dasatinib taken once-daily showcased the best safety profile, while achieving the same efficacy as the other dosing schedules in imatinib-resistant or -intolerant patients with CML-CP.

Treatment with dasatinib was generally well tolerated. Myelosuppression was frequently reported with dasatinib but was usually reversible and manageable by dose modifications. Nonhematological grade 1 or 2 adverse events such as musculoskeletal pain, headache, diarrhea, peripheral edema, fatigue, and nausea were commonly observed across all studies. The most common nonhematological grade 3 or 4 side effects from dasatinib treatment were pleural effusions. As shown by the Phase III dose finding trial by Shah et al, the incidence of pleural effusions was lower in patients receiving a dose of 100 mg once-daily than in those given 70 mg twice-daily dosing regimen.

Remarkably, treatment discontinuation occurred at rather high rates across all studies. This owes at least partially to the fact that the patient collective assessed in these studies had usually been heavily pretreated before therapy with dasatinib was initiated.

In summary, dasatinib treatment yields durable, long-term, major hematological, cytogenetic as well as molecular responses as a second-line treatment in CML-CP patients resistant or intolerant to imatinib. The long-term use of dasatinib is generally well tolerated. It is efficacious against most known BCR-ABL1 mutations conferring resistance to imatinib. In addition to its use in newly diagnosed CML-CP, dasatinib provides a safe and highly effective treatment option after initial failure of imatinib, and thus represents a valuable addition to the armamentarium of available first- and second-line BCR-ABL1 inhibitors.

Disclosure
The authors report no conflicts of interest in this work.

References


